Abstract
Purpose The aim of the study was to detect the effect of intravitreal ranibizumab injection on treatment of macular edema induced by central retinal vein occlusion (CRVO) or branch retinal vein occlusion (BRVO) by measuring the improvement in best-corrected visual acuity (BCVA) (LogMAR) and the reduction in central retinal thickness (CRT) measured by optical coherence tomography. Patients and methods In this prospective study, 50 patients with macular edema due to retinal vein occlusion (25 with CRVO and 25 with BRVO) received intravitreal injection of ranibizumab. Results A total of 12 weeks post-treatment, 68% of patients had an improvement in BCVA, 20% of patients remained stable, and 12% of patients had a decrease in BCVA. In addition, 56% of patients had decreased CRT exceeding 200 Mm and 30% of patients had decreased CRT exceeding 100 Mm. Conclusion Intravitreal injection of ranibizumab resulted in significant vision improvement and a decreased macular edema caused by CRVO or BRVO.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
